From: Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
Methylated MGMT
Unmethylated MGMT
Total pts
Partial Response
3 (1 GBM, 2 AA)
-
3
Stable Disease
5 (3 GBM, 2 AA)
5
Progression
4 (2 GBM, 2 AA)
7 (4 GBM, 2 AA, 1 AOA)
11
12
7
19